Plus Therapeutics to Present Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases
Plus Therapeutics (PSTV) announced the presentation of data from two clinical trials targeting recurrent glioblastoma and leptomeningeal metastases at the 2022 CNS Clinical Trials and Brain Metastases Conference on August 12-13, 2022. The oral presentation will focus on the safety and feasibility of Rhenium-186 Nanoliposome in leptomeningeal metastases, while a poster will cover its use in recurrent glioma as part of the ReSPECT Phase 1 Trial. This showcases advancements in innovative, targeted radiotherapeutics for challenging cancer types.
- Presentation of clinical trial data at a prominent conference highlights Plus Therapeutics' commitment to cancer treatment innovation.
- The focus on Rhenium-186 Nanoliposome indicates promising advancements in targeted radiotherapeutics for difficult cancers.
- None.
AUSTIN, Texas, July 28, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present data from two ongoing clinical trials for recurrent glioblastoma and leptomeningeal metastases at the 2022 Annual Conference on CNS Clinical Trials and Brain Metastases, co-sponsored by the Society for Neuro-Oncology (SNO) and the American Society of Clinical Oncology (ASCO), being held August 12-13, 2022 in Toronto, Canada.
Details of oral presentation:
| Title | LOCL-04: Safety and Feasibility of Rhenium-186 Nanoliposome (186RNL) in Leptomeningeal Metastases [LM] Phase 1/2a dose |
| Date | August 12, 2022 from 2:15 – 4:00 p.m. ET |
| Session | Oral abstract, Session 3: Enhancing Local and Compartmental Therapies |
| Presenter | Andrew J. Brenner, M.D., Ph.D., Associate Professor of Medicine, Neurology, and Neurosurgery at The University of Texas Health Science Center at San Antonio and principal investigator of the ReSPECT-LM clinical trial |
Details of poster presentation:
| Title | LOCL-08: Safety and Feasibility of Rhenium-186 NanoLiposome (186RNL) in Recurrent Glioma: the ReSPECT™ Phase 1 Trial |
| Date | August 12, 2022 from 6:20 – 8:20 p.m. ET |
| Session | Poster display, Poster and Networking Reception |
| Presenter | Andrew J. Brenner, M.D., Ph.D., Associate Professor of Medicine, Neurology, and Neurosurgery at The University of Texas Health Science Center at San Antonio and principal investigator of the ReSPECT-GBM clinical trial |
Electronic posters will be made available online at the start of the conference in addition to the in-person poster reception on Friday evening, August 12, 2022. For more information visit https://www.soc-neuro-onc.org/WEB/Event_Content/_2022_Annual_Conference_on_CNS_Clinical_Trials___Brain_Metastases.aspx
A copy of the posters will also be available under the Presentations tab of the Investors section of the Company’s website at the time of the presentations at https://ir.plustherapeutics.com.
About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases. Our proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. Our platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at PlusTherapeutics.com and ReSPECT-Trials.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186RNL including the ability of 186RNL to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM and ReSPECT-LM clinical trials; possible negative effects of 186RNL; the continued evaluation of 186RNL including through evaluations in additional patient cohorts; and the intended functions of the Company’s platform and expected benefits from such functions.
The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Peter Vozzo
ICR Westwicke
(443) 377-4767
Peter.Vozzo@westwicke.com
Media Contact
Terri Clevenger
ICR Westwicke
(203) 856-4326
Terri.Clevenger@westwicke.com
FAQ
What clinical trials data will Plus Therapeutics present at the 2022 conference?
When is Plus Therapeutics presenting data at the conference?
Who is presenting the data on Plus Therapeutics' clinical trials?
What is the significance of Rhenium-186 Nanoliposome in cancer treatment?
Where can I find more information about Plus Therapeutics' clinical trials?
